ERBB2 and neoplasm: Despite the generation in vitro of the neratinib-resistant variant of HER2-positive cell lines reported in the literature32, in our PDX models no appearance of resistance to neratinib in vivo was seen and tumor relapsing after drug interruption when implanted in other mice displayed again neratinib sensitivity.